Triple inhaled therapy for chronic obstructive pulmonary disease

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Abstract

Combining individual drugs in a single inhaler is the most convenient way to deliver triple therapy. A long-acting muscarinic receptor antagonist (LAMA) added to an inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA) fixed-dose combination (FDC) can improve efficacy of pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD). New inhaled ICS/LABA/LAMA FDCs, including fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium and beclometasone/formoterol/glycopyrronium, are in Phase III of clinical development for COPD. Triple inhaled therapy might be particularly useful in patients with severe to very severe COPD, above all in those with peripheral blood or sputum eosinophilia, asthma-COPD overlap syndrome (ACOS) or frequent exacerbators. Future prospective studies should assess efficacy and safety of triple ICS/LABA/LAMA therapy in selected COPD phenotypes.
Original languageEnglish
Pages (from-to)1820-1827
Number of pages8
JournalDrug Discovery Today
Volume21
Publication statusPublished - 2016

Keywords

  • LAMA
  • chronic obstructive pulmonary disease (COPD)
  • inhaled corticosteroids
  • triple inhaled therapy

Fingerprint

Dive into the research topics of 'Triple inhaled therapy for chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this